A Wiznia

Summary

Country: USA

Publications

  1. ncbi request reprint Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children
    Jacobo Abadi
    Division of Infectious Diseases, Department of Pediatrics, Jacobi Medical Center and Albert Einstein College of Medicine, 1400 Pelham Parkway, Bronx, NY, USA
    J Acquir Immune Defic Syndr 41:298-303. 2006
  2. ncbi request reprint Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
    A Wiznia
    Pediatric HIV Services, Jacobi Medical Center, Bronx, New York 10461, USA
    AIDS Res Hum Retroviruses 16:1113-21. 2000
  3. ncbi request reprint Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients
    Andrew Wiznia
    Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Pediatr Infect Dis J 26:799-805. 2007
  4. pmc Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy
    Joseph S Cervia
    Albert Einstein College of Medicine, Bronx, NY 11030, USA
    Pediatr Infect Dis J 29:1118-22. 2010
  5. ncbi request reprint Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children
    Joseph A Church
    Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
    Pediatr Infect Dis J 23:713-8. 2004
  6. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
  7. ncbi request reprint Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1
    Elizabeth R Sharp
    Gladstone Institute of Virology and Immunology, San Francisco General Hospital, University of California, 94158, USA
    J Infect Dis 192:1772-80. 2005
  8. ncbi request reprint A behavioral and cognitive profile of clinically stable HIV-infected children
    Molly L Nozyce
    Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York, USA
    Pediatrics 117:763-70. 2006
  9. ncbi request reprint Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
    Pediatr Infect Dis J 21:119-25. 2002
  10. ncbi request reprint CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093 0672, USA
    AIDS 21:2191-9. 2007

Collaborators

  • A Kovacs
  • P Yu
  • W Borkowsky
  • P Krogstad
  • Joseph S Cervia
  • Caroline J Chantry
  • L M Mofenson
  • Sharon Nachman
  • M Bamji
  • Molly L Nozyce
  • Akihiko Saitoh
  • Edmund V Capparelli
  • Rita J Jeremy
  • Joseph A Church
  • Else Smith
  • Robert M Grant
  • E P Acosta
  • C V Fletcher
  • JAY B JACKSON
  • Ram Yogev
  • Johan K Sandberg
  • Michael G Rosenberg
  • Joanna Dobroszycki
  • Jennifer R King
  • Douglas F Nixon
  • Christopher Okunseri
  • Glenn Fennelly
  • Kimberly A Jordan
  • Y J Bryson
  • Xavier Saez-Llorens
  • Jacobo Abadi
  • Stephen I Pelton
  • Elizabeth R Sharp
  • Stephen Pelton
  • Jason D Barbour
  • Kenneth Stanley
  • Bharat Damle
  • Kenneth McIntosh
  • Janice Hodge
  • Grace Aldrovandi
  • Michael Rosenberg
  • Victor Badner
  • Noam M Fast
  • Mary E Keir
  • Laura W Sheehan
  • D H Watts
  • Dalubuhle Ndiweni
  • Maria Mercedes Castrejon
  • Joseph Stavola
  • M D Hughes
  • Stephen A Spector
  • Franck Rousseau
  • Wanda Biernick
  • Milagros Gonzalez
  • Xavier Saez Llorens
  • Maureen Shannon
  • Jhoanna Roa
  • Kenneth Boyer
  • Deborah Goldman
  • Nathalie Adda
  • Patricia Franklin
  • S Huang
  • Avy Violari
  • Miguel Cashat
  • Michele Acker
  • Alice Stek
  • Karin Nielsen
  • J Connor
  • Kimberly Hughes
  • Ana Puga
  • Karen Dorio
  • Sohail Rana
  • Bonnie J Ank
  • Patricia Flynn
  • Deepika Darbari
  • Ellen Cooper
  • Maryanne Dillon
  • K Kaiser
  • Judy Hayes
  • Laureen Kaye
  • Anne Marie Regan
  • Y Asfaw
  • Jane Hitti
  • L Purdue
  • Andrew D Hull
  • John Hinkle
  • M Mirochnick
  • M Keller
  • M Robert Blum
  • Nasser Redjal

Detail Information

Publications24

  1. ncbi request reprint Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children
    Jacobo Abadi
    Division of Infectious Diseases, Department of Pediatrics, Jacobi Medical Center and Albert Einstein College of Medicine, 1400 Pelham Parkway, Bronx, NY, USA
    J Acquir Immune Defic Syndr 41:298-303. 2006
    ..Therapy simplification by PTI may provide a practical option in patients intolerant of or failing PI-based highly active antiretroviral therapy...
  2. ncbi request reprint Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
    A Wiznia
    Pediatric HIV Services, Jacobi Medical Center, Bronx, New York 10461, USA
    AIDS Res Hum Retroviruses 16:1113-21. 2000
    ..A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population...
  3. ncbi request reprint Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients
    Andrew Wiznia
    Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Pediatr Infect Dis J 26:799-805. 2007
    ..Enfuvirtide is the only entry inhibitor approved for the treatment of human immunodeficiency virus (HIV)-1 infection. It is approved for use in adults and dosage recommendations exist for children aged 6 years or older...
  4. pmc Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy
    Joseph S Cervia
    Albert Einstein College of Medicine, Bronx, NY 11030, USA
    Pediatr Infect Dis J 29:1118-22. 2010
    ....
  5. ncbi request reprint Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children
    Joseph A Church
    Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
    Pediatr Infect Dis J 23:713-8. 2004
    ..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide...
  6. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
    ..We tested the efficacy, tolerability and pharmacokinetics of 2 combination therapies containing an NRTI, protease inhibitors +/- a nonnucleoside reverse transcription inhibitor (NNRTI)...
  7. ncbi request reprint Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1
    Elizabeth R Sharp
    Gladstone Institute of Virology and Immunology, San Francisco General Hospital, University of California, 94158, USA
    J Infect Dis 192:1772-80. 2005
    ..01) than Hispanic children; this was significantly driven by robust responses in African American girls near the age of puberty, many of whom carried the human leukocyte antigen class I B*58 allele...
  8. ncbi request reprint A behavioral and cognitive profile of clinically stable HIV-infected children
    Molly L Nozyce
    Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York, USA
    Pediatrics 117:763-70. 2006
    ..The purpose of this research was to characterize behavioral and cognitive profiles of clinically and immunologically stable antiretroviral-experienced HIV-infected children...
  9. ncbi request reprint Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
    Pediatr Infect Dis J 21:119-25. 2002
    ..Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination...
  10. ncbi request reprint CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093 0672, USA
    AIDS 21:2191-9. 2007
    ....
  11. doi request reprint Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects
    Xavier Saez-Llorens
    Infectious Disease Department, Hospital del Nino, Panama City, Panama
    Pediatrics 121:e827-35. 2008
    ....
  12. doi request reprint Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
    Y J Bryson
    David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1752, USA
    HIV Clin Trials 9:115-25. 2008
    ..We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women...
  13. ncbi request reprint Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children
    Stephen I Pelton
    Boston Medical Center, Boston, MA 02118, USA
    Clin Infect Dis 40:1181-7. 2005
    ....
  14. ncbi request reprint Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children
    Rita J Jeremy
    Pediatric Clinical Research Center, Department of Pediatrics, School of Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 0105, USA
    Pediatrics 115:380-7. 2005
    ..Neuropsychological functioning and its correlation with viral load were investigated for previously treated HIV-infected children who underwent a change in treatment regimen...
  15. ncbi request reprint Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1
    Paul Krogstad
    University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA
    Clin Infect Dis 34:991-1001. 2002
    ..These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia...
  16. pmc Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection
    Johan K Sandberg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 76:7528-34. 2002
    ..These data indicate that the key immunoregulatory NKT-cell compartment is compromised in HIV-1-infected patients...
  17. ncbi request reprint Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus
    Mary E Keir
    Biomedical Sciences Graduate Program, University of California, San Francisco 94143, USA
    J Immunol 169:2788-96. 2002
    ..We suggest that this HIV-1-initiated selection process may contribute to the generation of dysfunctional CD8(+) T cells in HIV-1-infected patients...
  18. ncbi request reprint Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children
    Joseph A Church
    Department of Pediatrics, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, 90027, USA
    Pediatr Infect Dis J 21:653-9. 2002
    ..The fusion inhibitor T-20 is the first in this new class, and the present study is the first to examine chronic s.c. administration of T-20 to HIV-1-infected children...
  19. ncbi request reprint Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Ala, USA
    Antivir Ther 7:267-70. 2002
    ....
  20. ncbi request reprint Prevalence of oral lesions and percent CD4+ T-lymphocytes in HIV-infected children on antiretroviral therapy
    Christopher Okunseri
    Department of Community Dentistry, Montefiore Medical Center, Affiliate of the Albert Einstein College of Medicine, Bronx, New York 55455, USA
    AIDS Patient Care STDS 17:5-11. 2003
    ..001). Compared to previous studies, overall prevalence estimates of oral lesions in this study was low. Children with low CD4 percent had more oral lesions, consistent with results from other HIV studies...
  21. ncbi request reprint HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment
    Johan K Sandberg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94141, USA
    J Immunol 170:4403-10. 2003
    ..The results are discussed in relation to differences between the neonatal and adult immune systems in the ability to respond to HIV infection...
  22. ncbi request reprint Dental visits by pediatric HIV-infected medical patients
    Christopher Okunseri
    N Y State Dent J 69:26-9. 2003
    ..The researchers believe that the study showed that a significant number of HIV-infected children on public insurance programs receiving consistent medical care had not visited any dental provider...
  23. ncbi request reprint Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection
    Courtney V Fletcher
    Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 24:453-9. 2004
    ..To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV)...
  24. ncbi request reprint Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy
    Sharon A Nachman
    Department of Pediatrics, State University of New York Health Science Center at Stony Brook, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 156:497-503. 2002
    ..Human immunodeficiency virus (HIV)-infected children often suffer from impaired growth. Highly active antiretroviral therapy (HAART) successfully reduces HIV 1 (HIV-1) RNA to 400 copies/mL or less in many children...